Evidence map›Paper›PMID 30671696›Full record

ReviewCellular and molecular neurobiology2019

Recent Expansions on Cellular Models to Uncover the Scientific Barriers Towards Drug Development for Alzheimer's Disease.

Sunil Kumar Dubey, Munnangi Siva Ram, Kowthavarapu Venkata Krishna, Ranendra Narayan Saha, Gautam Singhvi, Mukta Agrawal, Ajazuddin, Swarnlata Saraf, Shailendra Saraf, Amit Alexander

Open access · greenAbstract readReview
In one paragraph

Review in Cellular and molecular neurobiology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
3.6field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 65 citations in OpenAlex.

  1. Evaluation of the In Vitro Blood-Brain Barrier Transport ofInternational journal of molecular sciences · 2025
    Article
  2. Article
  3. Role of Liposomes in the Treatment of Neurodegenerative Disorders: A Comprehensive Review.Central nervous system agents in medicinal chemistry · 2025
    Review
  4. Review
  5. Review
  6. A Perspective: Challenges in Dementia Research.Medicina (Kaunas, Lithuania) · 2022
    Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Review
  13. Analysis of L-leucine amino acid transporter species activity and gene expression by human blood brain barrier hCMEC/D3 model reveal potential LAT1, LAT4, BJournal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism · 2022
    Article
  14. Article
  15. Review
  16. Article
  17. Review
  18. Article
  19. NeuroinflammatoryFrontiers in pharmacology · 2021
    Review
  20. Evodiamine derivatives improve cognitive abilities in APPAnimal models and experimental medicine · 2020
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 2 countries.

Sunil Kumar DubeyDepartment of Pharmacy, Birla Institute of Technology and Science, Pilani (BITS-PILANI), Pilani Campus, Rajasthan, India. skdubey@pilani.bits-pilani.ac.in.ORCID http://orcid.org/0000-0002-7554-3232
Munnangi Siva RamDepartment of Pharmacy, Birla Institute of Technology and Science, Pilani (BITS-PILANI), Pilani Campus, Rajasthan, India.
Kowthavarapu Venkata KrishnaDepartment of Pharmacy, Birla Institute of Technology and Science, Pilani (BITS-PILANI), Pilani Campus, Rajasthan, India.
Ranendra Narayan SahaDepartment of Biotechnology, Birla Institute of Technology and Science, Pilani (BITS-PILANI), Dubai Campus, Dubai, United Arab Emirates.
Gautam SinghviDepartment of Pharmacy, Birla Institute of Technology and Science, Pilani (BITS-PILANI), Pilani Campus, Rajasthan, India.
Mukta AgrawalDepartment of Pharmaceutics, Rungta College of Pharmaceutical Sciences and Research, Kohka, Kurud Road, Bhilai, Chhattisgarh, 490024, India.
AjazuddinDepartment of Pharmaceutics, Rungta College of Pharmaceutical Sciences and Research, Kohka, Kurud Road, Bhilai, Chhattisgarh, 490024, India.
Swarnlata SarafUniversity Institute of Pharmacy, Pt. Ravishankar Shukla University, Raipur, 492 010, Chhattisgarh, India.
Shailendra SarafUniversity Institute of Pharmacy, Pt. Ravishankar Shukla University, Raipur, 492 010, Chhattisgarh, India.
Amit AlexanderDepartment of Pharmaceutics, Rungta College of Pharmaceutical Sciences and Research, Kohka, Kurud Road, Bhilai, Chhattisgarh, 490024, India. itsmeamitalex@gmail.com.ORCID http://orcid.org/0000-0003-0391-7650
Birla Institute of Technology and Science, Pilani · INChhattisgarh Kamdhenu Vishwavidyalaya · INBirla Institute of Technology and Science, Pilani - Dubai Campus · AEHindu College of Pharmacy · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Globally, the central nervous system (CNS) disorders appear as the most critical pathological threat with no proper cure. Alzheimer's disease (AD) is one such condition frequently observed with the aged population and sometimes in youth too. Most of the research utilizes different animal models for in vivo study of AD pathophysiology and to investigate the potency of the newly developed therapy. These in vivo models undoubtably provide a powerful investigation tool to study human brain. Although, it sometime fails to mimic the exact environment and responses as the human brain owing to the distinctive genetic and anatomical features of human and rodent brain. In such condition, the in vitro cell model derived from patient specific cell or human cell lines can recapitulate the human brain environment. In addition, the frequent use of animals in research increases the cost of study and creates various ethical issues. Instead, the use of in vitro cellular models along with animal models can enhance the translational values of in vivo models and represent a better and effective mean to investigate the potency of therapeutics. This strategy also limits the excessive use of laboratory animal during the drug development process. Generally, the in vitro cell lines are cultured from AD rat brain endothelial cells, the rodent models, human astrocytes, human brain capillary endothelial cells, patient derived iPSCs (induced pluripotent stem cells) and also from the non-neuronal cells. During the literature review process, we observed that there are very few reviews available which describe the significance and characteristics of in vitro cell lines, for AD investigation. Thus, in the present review article, we have compiled the various in vitro cell lines used in AD investigation including HBMEC, BCECs, SHSY-5Y, hCMEC/D3, PC-2 cell line, bEND3 cells, HEK293, hNPCs, RBE4 cells, SK-N-MC, BMVECs, CALU-3, 7W CHO, iPSCs and cerebral organoids cell lines and different types of culture media such as SCM, EMEM, DMEM/F12, RPMI, EBM and 3D-cell culture.

Indexed as

Drug DevelopmentModels, BiologicalAlzheimer DiseaseAnimalsCell Culture TechniquesCell LineEndothelial CellsHumansAlzheimer’s diseaseBCECsHBMECIn vitro cell lineSK-N-MC

Identifiers

PMID30671696
PMCPMC11469828
OpenAlexW2911884446

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.